The Canadian Cardiovascular Society (CCS) recently published a guideline for the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) to reduce the risks of cardiorenal morbidity and mortality in individuals living with heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes (T2D) with either concomitant atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD [1]. The gene discussed is GLP1R; the disease is chronic kidney disease.